- Home
- NUW vs LUNG Comparison
NUW vs LUNG Comparison
Compare NUW & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NUW | LUNG |
|---|---|---|
| Founded | 2008 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 254.4M | 63.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NUW | LUNG |
|---|---|---|
| Price | $14.25 | $2.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 45.3K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 3.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $12.45 | $1.31 |
| 52 Week High | $14.44 | $9.37 |
Technical Indicators
Market Signals| Indicator | NUW | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 69.54 |
| Support Level | $14.15 | $2.43 |
| Resistance Level | $14.44 | $2.66 |
| Average True Range (ATR) | 0.10 | 0.20 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 56.25 | 90.37 |
Price Performance
Historical ComparisonAbout NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.